New evidence for tamoxifen as an antischistosomal agent: in vitro, in vivo and target fishing studies

Future Med Chem. 2021 Jun;13(11):945-957. doi: 10.4155/fmc-2020-0311. Epub 2021 Apr 26.

Abstract

Background: Praziquantel is the only drug available to treat schistosomiasis, and there is an urgent demand for new anthelmintic agents. Methodology & results: We conducted in-depth in vitro and in vivo studies and report a target fishing investigation. In vitro, tamoxifen was active against adult and immature worms at low concentrations (<5 μM). Tamoxifen at a single dose (400 mg/kg) or once daily for five consecutive days (100 mg/kg/day) in mice harboring either adult (patent infection) or juvenile (prepatent infection) significantly reduced worm burden (30-70%) and egg production (70-90%). Target fishing studies revealed propionyl-CoA carboxylase as a potential target for tamoxifen in Schistosoma mansoni and glucose uptake by S. mansoni was also significantly reduced. Conclusion: Our results provide news evidence of antiparasitic effect of tamoxifen and reveal propionyl-CoA carboxylase as a potential target.

Keywords: Schistosoma; antischistosomal compound; drug repositioning; schistosomiasis; tamoxifen; target fishing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal
  • Female
  • Mice
  • Schistosoma mansoni / drug effects*
  • Schistosomiasis / drug therapy*
  • Schistosomicides / chemistry
  • Schistosomicides / pharmacology*
  • Tamoxifen / chemistry
  • Tamoxifen / pharmacology*

Substances

  • Schistosomicides
  • Tamoxifen